# Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

* Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.
* The company’s current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies.
* SGX302 has already demonstrated positive results in a phase 1/2 pilot study.

 Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The company has already seen encouraging signals in earlier proof-of-concept work, and with its current study underway, Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions.

 The psoriasis trial, officially registered as NCT05442190, is designed as a phase 2a open-label study evaluating SGX302, a synthetic hypericin formulation, in patients with mild-to-moderate disease. Building on earlier positive phase 1/2 proof-of-concept data, this current study aims to further assess safety and…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/soligenix-inc-nasdaq-sngx-advances-psoriasis-trial-with-encouraging-patient-results-market-potential/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-advances-promising-psoriasis-treatment-in-phase-2-trial/78585528350f69c7534e668f07cc7eef) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/29/gluelrQy.webp)